Phase III Acute Coronary Syndrome

• Status: Terminated
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborators: Duke Clinical Research Institute; Pfizer
• Treatments: Apixaban

Criteria

Inclusion Criteria:

• Acute coronary syndrome (ACS)

• Clinically stable

• Receiving standard of care for ACS

Exclusion Criteria:

• Severe hypertension

• Active bleeding or high risk for major bleeding

• Hemoglobin < 9 g/dL